Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Urinary Bladder CancerBladder CancerBladder NeoplasmsBladder Tumors
Interventions
DRUG

Vicinium

Intravesical administration of Vicinium

Trial Locations (21)

21287

Johns Hopkins Medical Institutions, Baltimore

23606

Urology of Virginia, Newport News

27710

Duke University Medical Center, Durham

29572

Grand Strand Urology, Myrtle Beach

32308

Southeastern Research Group, Inc., Tallahassee

78404

Corpus Christi Urology Group, LLP, Corpus Christi

97477

Oregon Urology Institute Research, Springfield

08648

Lawrenceville Urology, Lawrenceville

V3V 1N1

Andreou Research, Surrey

V8T 5G9

Can-Med Clinical Research Inc., Victoria

L4M 7G1

The Male/Female Health and Research Centre, Royal Court Medical Centre, Barrie

L7S 1V2

Urology Resource Centre, Burlington

L8N 4A6

McMaster University, Institute of Urology at Saint Joseph's Hospital, Hamilton

K7L 2V7

Centre for Applied Urological Research, Kingston

N6A 4G5

London Health Sciences Centre, London

L6H 3P1

The Fe/Male Health Centre, Oakville

N4K 2J1

Todd Webster, M.D., Owen Sound

M1P 2T7

The Scarborough Hospital, Scarborough Village

M4N 3M5

University of Toronto, Sunnybrook Health Sciences Centre, Toronto

M5G 2M9

Princess Margaret Hospital, Toronto

J1H 5N4

Centre Hospitalier Universitaire de Sherbrooke, Hopital Fleuimont, Sherbrooke

All Listed Sponsors
lead

Sesen Bio, Inc.

INDUSTRY

NCT00462488 - Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ | Biotech Hunter | Biotech Hunter